Cisplatin-Based Three Drugs Combination (NIP) as Induction and Adjuvant Treatment in Locally Advanced Non-small Cell Lung Cancer: Final Results Maya.

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Oral Vinorelbine and Cisplatin as Induction Chemotherapy and Concomitant Chemo- Radiotherapy in Stage III Non-small Cell Lung Cancer: Final Results of.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer Rodryg Ramlau, MD,

SC17.02 Lung Cancer in China: Challenges and Perspectives

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

Multimodality Treatment of Stage III Non-small Cell Lung Cancer: Analysis of a Phase II Trial Using Preoperative Cisplatin and Gemcitabine with Concurrent.

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Electronic Updates for JTO Readers

Hedgehog Signaling Pathway and Lung Cancer

Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation Jean-Yves.

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer W Jeffrey Petty, MD, Sommer N.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Thymoma: A Population-Based Study of the Management and Outcomes for the Province of British Columbia Caroline Mariano, MD, Diana N. Ionescu, MD, Winson.

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Randomized Phase II Study of Palifermin for Reducing Dysphagia in Patients Receiving Concurrent Chemoradiotherapy for Locally Advanced Unresectable Non-small.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Erratum Journal of Thoracic Oncology

Outcomes of Mediastinoscopy and Surgery with or without Neoadjuvant Therapy in Patients with Non-small Cell Lung Cancer Who are N2 Negative on Positron.

Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older Yuh-Min Chen,

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III.

Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients

A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer Thomas E. Stinchcombe, MD, Harry.

Dose-per-Fraction Escalation of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Long-Term Results of Radiofrequency Ablation Treatment of Stage I Non-small Cell Lung Cancer: A Prospective Intention-to-Treat Study Marcello Carlo Ambrogi,

The Role of Histology with Common First-line Regimens for Advanced Non-small Cell Lung Cancer: A Brief Report of the Retrospective Analysis of a Three-arm.

Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.

Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study Alex Chang, MD,

Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early- Stage Non–Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized.

Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced.

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer Giulia Veronesi, MD, Paolo Scanagatta, MD, Francesco Leo, MD, Tommaso.

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.

Ethnic Differences in Survival Outcome in Patients with Advanced Stage Non-small Cell Lung Cancer: Results of a Meta-Analysis of Randomized Controlled.

A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 Ramaswamy Govindan, MD, Xiaofei.

European Lung Cancer Conference (ELCC) 2016 Organisation

Oral Vinorelbine and Cisplatin as Induction Chemotherapy and Concomitant Chemo- Radiotherapy in Stage III Non-small Cell Lung Cancer: Final Results of.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Impact of Information on Quality of Life and Satisfaction of Non-small Cell Lung Cancer Patients: A Randomized Study of Standardized versus Individualized.

Induction Therapy For Locally Advanced Thymoma

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive.

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non- small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.

A Review of First-Line Treatment for Small-cell Lung Cancer

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Mark A. Socinski, MD Journal of Thoracic Oncology

Presentation transcript:

Cisplatin-Based Three Drugs Combination (NIP) as Induction and Adjuvant Treatment in Locally Advanced Non-small Cell Lung Cancer: Final Results Maya Gottfried, MD, Rodryg Ramlau, MD, Maciej Krzakowski, MD, Grzegorz Ziolo, MD, Henryk Olechnowicz, MD, Leona Koubkova, MD, Jubrail Dahabreh, MD, Aleksandra Szczesna, MD, Guillermo Lopez Vivanco, MD, Reury-Perng Perng, MD, Francesco Carpagnano, MD, Swan-Swan Leong, MD, Alberto Fittipaldo, MD, Cecilia De Almeida, MSc, Delphine Aubert, MD, Dominique Grunenwald, MD Journal of Thoracic Oncology Volume 3, Issue 2, Pages 152-157 (February 2008) DOI: 10.1097/JTO.0b013e318160c0e7 Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Study flow chart. Journal of Thoracic Oncology 2008 3, 152-157DOI: (10.1097/JTO.0b013e318160c0e7) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Overall survival from registration. Journal of Thoracic Oncology 2008 3, 152-157DOI: (10.1097/JTO.0b013e318160c0e7) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Disease-free survival from registration. Journal of Thoracic Oncology 2008 3, 152-157DOI: (10.1097/JTO.0b013e318160c0e7) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Overall survival from randomization. Journal of Thoracic Oncology 2008 3, 152-157DOI: (10.1097/JTO.0b013e318160c0e7) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions